Oncohema Key

Targeted treatment combined with docetaxel Phase I docetaxel combination trial in CRPC, N Any unexpected safety signals? Pharmacodynamic studies Phase II docetaxel-combination trial in CRPC design (N) Statistical plan Primary…

Fig. 19.1 Schematic examples of HGF/MET and/or VEGF/VEGFR inhibitors mechanism of action. VEGFR vascular endothelial growth factor receptor, PDGFR platelet-derived growth factor receptor, HGF hepatocyte growth factor, FLT3 FMS-like tyrosine…

Fig. 15.1 TGF-β transforming growth factor-β; HGF hepatocyte growth factor; VEGF vascular endothelial growth factor; PLGF placental growth factor; Ang angiopoietin; PDGF platelet-derived growth factor; FGF fibroblast growth factor Although…

Phenotype Molecular basis Mechanism Consequence AR-addicted Adrenal or intra-tumoral androgen biosynthesis Androgens produced sufficient to activate AR Responds to androgen biosynthesis inhibitors and selected AR antagonists AR mutation Alters ligand…

Fig. 5.1 Schematic of the full-length androgen receptor and exon structure of major splice variants (ARV7 (b) and ARV567 (c)). Domains of AR include the amino (N) terminal domain, the…

Fig. 10.1 The vicious cycle of bone metastases Transforming growth factor beta (TGFβ) is released from resorbed bone matrix and has been shown to augment signaling through parathyroid hormone-related protein…

Target Agent(s) Phase Summary Identifier mTOR Everolimus (Docetaxel) (Bevacizumab) Ib/II Dose-finding/efficacy study; Docetaxel + everolimus + bevacizumab in metastatic CRPC NCT00574769 mTOR Temsirolimus (Bevacizumab) I/II Dose-finding/efficacy study; Temsirolimus + bevacizumab in metastatic CRPC NCT01083368 mTOR Everolimus…